Zhejiang Xianju Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") has recently received the "Drug Supplement Application Approval Notice" (Notice No. 2026B03041) issued by the National Medical Products Administration for progesterone injection 1ml:50mg. The company's progesterone injection has passed the consistency evaluation for the quality and efficacy of generic drugs. The relevant information is announced as follows:
002332SZSE
Announcement on the Consistency Evaluation Approval of Progesterone Injection
✨ AI Summary
Zhejiang Xianju Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for its progesterone injection (1ml:50mg) to pass the consistency evaluation for quality and efficacy. This approval enhances the company's gynecological product line and market competitiveness. However, investors are advised to be aware of potential risks associated with drug development, production, and sales influenced by national policies and market conditions.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.